UnitedHealth Slips 3% as TPG Buys Into Florida WellMed Clinics Ahead of Guidance Reaffirmation
TPG just bought into the exact Optum clinics that derailed UnitedHealth's profits, and management is hours away from reaffirming guidance that could either validate the deal or reopen a wound investors hoped was healing.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
UnitedHealth Group (NYSE:UNH | UNH Price Prediction) stock is down 3% to $388.58 in early Wednesday trading after Bloomberg reported the company sold an interest in part of its Florida WellMed primary-care clinics. The 3% slide comes even as UnitedHealth stock is still up 15% year to date, and it lands hours before management is set to reaffirm full-year 2026 financial guidance at an investor conference, according to UnitedHealth Group.
TPG (NASDAQ:TPG) is the buyer. The Fort Worth alternative asset manager ended Q2 2026 with $326.8 billion in assets under management and $76.2 billion in available capital, and its Capital and Healthcare Partners platforms have been active in senior-care buyouts.
WellMed sits inside Optum Health, the value-based care unit whose stumbles drove UnitedHealth’s ongoing turnaround. The reaction today looks company-specific rather than sector-wide, and that framing matters for anyone reading through from UnitedHealth into the broader managed-care group.
Selling a Piece of the Problem Child
Bloomberg reported Tuesday evening that UnitedHealth sold an interest in some of its Optum Health operations in Florida to TPG, centered on WellMed’s senior primary-care clinics. Terms weren’t disclosed, which leaves investors valuing a transaction with no headline dollar figure attached to it.
Chief Financial Officer Wayne DeVeydt told Bloomberg, “We didn’t need the dollars, we have the dollars to invest, but we needed the focus and somebody that could actually work with us locally.” He described the arrangement as a way to grow the clinic footprint faster than UnitedHealth could on its own while it executes a wider reset.
DeVeydt also told the outlet that Optum Health margins will reach 2% this year, ahead of prior expectations, and he guided to 4% next year. That trajectory matters because Optum Health was the source of last year’s disappointing profit and the reason the company replaced its chief executive and other senior leaders.
UnitedHealth reported Optum Health revenue of $23.47 billion in Q2 2026, down 5% year over year (YoY) as the unit shed 700,000 value-based care patients. The WellMed carve-in gives Optum a well-capitalized operating partner and hands TPG a foothold in Medicare-focused primary care during a stretch when the sector’s economics remain contested.
Sector Barely Flinches
The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is down 0.4% to $166.44, a fraction of UnitedHealth’s move and a sign the story isn’t reading as a broader healthcare selloff. UnitedHealth is a top-five weight in the fund at 6.57% of net assets, so a heavier sector drop would be showing up if the news were spilling into the group.
The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is down 0.35% to $763.31, so the broad tape is merely soft. Managed-care peers Elevance Health (NYSE:ELV), Cigna (NYSE:CI), and Humana (NYSE:HUM) aren’t posting a matching drop, which reinforces that today’s move is UnitedHealth-specific.
The tension is philosophical. A turnaround company is selling a slice of the exact division that caused the damage, and readers can view that as discipline or as retreat. Without transaction terms, both interpretations have room to breathe.
What to Watch
DeVeydt said UnitedHealth expects to reaffirm its financial guidance at an investor conference hosted by Wells Fargo (NYSE:WFC). That reaffirmation is the more meaningful near-term catalyst, since the July update lifted UnitedHealth’s full-year adjusted EPS guidance to $19.50 to $20 and raised the company’s operating cash flow outlook to $24 billion.
Analyst consensus for UnitedHealth’s full-year 2026 adjusted EPS sits at $19.81, inside management’s raised range, and the 2027 consensus sits at $22.44. A clean reaffirmation would keep those numbers intact, while any hedging language on Optum Health could reopen the debate the WellMed deal is trying to settle.
Investors could look for signs that UnitedHealth’s management ties the WellMed partnership to specific clinic growth targets or Optum margin milestones on stage. Position sizing on one’s UnitedHealth stock exposure may deserve a fresh look given today’s gap between the stock and its sector fund.
Contact [email protected] for any questions or corrections.
David Moadel is financial writer specializing in stocks, ETFs, options, precious metals, and Bitcoin. David has written well over 1,000 articles for leading online publications, helping investors understand markets, income strategies, and risk.His work has appeared in The Motley Fool, InvestorPlace, U.S. News & World Report, TipRanks, ValueWalk, Benzinga, Market Realist, TalkMarkets, Finmasters, 24/7 Wall St., and others.With a master’s degree in education, David has taught at the elementary, high school, and college levels. That teaching background shapes his writing style: clear, educational, and practical. David has also built a loyal social-media audience by providing trustworthy financial content on YouTube, X/Twitter, and StockTwits.
